Dabrafenib Mesylate

甲磺酸达拉非尼

Report date: 2026/05/23 20:00:57
NME

Base Information

Drug NameDabrafenib Mesylate
Drug Alias Name达拉非尼Dabrafenibum达拉菲尼DabrafenibTafinlar +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase B-raf inhibitorsC-Raf kinase inhibitors
TargetsC-Raf kinaseSerine/threonine-protein kinase B-raf
Therapy Area/IndicationsSolid tumoursLymphoproliferative DisordersErdheim-Chester Disease +[21] 
Global Approved IndicationsMelanoma
Approved Indications in ChinaMelanoma
Original Approved Country/TerritoryUnited States
Original Approved Date2013/05/29
Country/TerritoryCzechiaBelgiumCanada +[38] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharmaceuticals Uk LtdShandong UniversityNovartis Pharma Ag +[7] 
Inactive CompaniesUtah State UniversityBristol Myers Squibb SrlcompanyUniversity Of California San Francisco +[13] 
Active IndicationsSolid tumoursLymphoproliferative DisordersErdheim-Chester Disease +[18] 
Inactive IndicationsRenal InsufficiencyHepatic InsufficiencyNeoplasms

Other Information

ATC CodeL01EC02
Related LinksWikipediaDrugBankKEGG